藥明巨諾-B(02126.HK)「倍諾達」於中國成人復發或難治性濾泡性淋巴瘤患者有良好臨床反應
藥明巨諾-B(02126.HK)公布,在第64屆美國血液學會年會上公布倍諾達(瑞基奧侖賽注射液)分別在中國成人復發/難治性濾泡淋巴瘤及復發/難治性套細胞淋巴瘤患者中的最新臨床數據。
集團指,在中國成人復發/難治性濾泡性淋巴瘤患者中,基於28例受試者的中位隨訪11.7個月的結果,瑞基奧侖賽展現良好的臨床反應,實現了較高的完全緩解率和客觀緩解率,且安全性良好,預期將在更長的隨訪時間後,披露更新的安全性和療效數據。至於在中國成人復發/難治性套細胞淋巴瘤患者中的初步安全性和有效性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.